Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B

• Published in: Journal of antimicrobial chemotherapy Vol. 68; no. 6; pp. 1243 - 1245
• Main Authors: Soulie, C., Lambert-Niclot, S., Fofana, D. B., Fourati, S., Ait-Arkoub, Z., Sayon, S., Simon, A., Katlama, C., Calvez, V., Marcelin, A.-G.
• Format: Journal Article
• Language: English
• Published: England Oxford Publishing Limited (England) 01.06.2013
• Subjects: Amino Acid Sequence; Amino Acid Substitution - genetics; Amino acids; Anti-HIV Agents - pharmacology; CD4 Antigens - drug effects; Drug resistance; Drug Resistance, Viral - genetics; HIV; HIV Envelope Protein gp120 - drug effects; HIV Envelope Protein gp120 - genetics; HIV Infections - genetics; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Inhibitor drugs; Mutation; Piperazines - pharmacology; Real-Time Polymerase Chain Reaction; Triazoles - pharmacology; Viral Tropism - drug effects; Virus Attachment - drug effects; primary resistance; tropism; gp120
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkt018

Resistance to attachment inhibitor BMS-626529, which inhibits the binding of HIV to CD4, involves mutations in the HIV-1 gp120 gene. There is a lack of information on the primary resistance of HIV-1 subtype B to attachment inhibitors, so we decided to investigate. Sequences from 109 attachment-inhibitor-naive patients infected with HIV-1 subtype B were analysed for the presence of previously described in vivo resistance mutations associated with attachment inhibitor BMS-626529 and tropism determination. The M426L substitution associated with a reduced efficacy of the attachment inhibitor BMS-626529 was present at 7.3%. There was no difference in mutation distribution according to virus tropism (R5 or X4). The attachment inhibitor BMS-626529 is suitable for most patients infected with HIV-1 subtype B.